Inclusion Criteria:

•Women with metastatic breast cancer •Completing planned course of therapy with planned treatment break •Measurable or evaluable disease •Estimated survival of at least 3 months •Planned to be off therapy at least 1 month •No platelet inhibitor therapy within 1 month of study entry •Platelets >100,000 •Coagulation screening tests within normal range—INR between 1.0 and 1.4 •Normal kidney and liver function as defined by:

• AST/ALT < 2 x Institutional Normal
• Creatinine < 2 x Institutional Normal

Exclusion Criteria:

•Patients going on to endocrine therapy •Patients going on to surgery •Patients with a serious bleeding disorder that contraindicate the use of platelet function inhibitors •Patients with history of significant bleeding related to peptic ulcer disease •Patients on standing doses of NSAIDS or platelet function inhibitors •Patients on standing doses of anti-coagulants